Table 1.
Clinical characteristics of cerebrospinal fluid sample analysis.
| Discovery Cohort (n = 65) | ||||||
| Groups | Total |
Cancer Control
(n = 11) |
Healthy Control
(n = 12) |
LM
(n = 22) |
Brain Metastasis
(n = 11) |
Brain Tumors
(n = 9) |
| Gender | ||||||
| Male | 29 | 5 | 4 | 13 | 3 | 4 |
| Female | 36 | 6 | 8 | 9 | 8 | 5 |
| Median age (range) |
56 (2.3–78) |
9.0 (2.3–78) |
61 (49–72) |
57 (36–71) |
47 (33–68) |
30 (10–76) |
| Primary disease (n) |
Leukemia (4) Lymphoma (2) Breast ca. (1) Cholangioca. (1) Chordoma (1) GCT (1) Melanoma (1) |
Unruptured An. (10) Hydrocephalus (2) |
NSCLC (16) Breast ca. (4) Ovarian ca (2) |
NSCLC (5) Melanoma (3) Breast ca. (2) HCC (1) |
Glioma (3) Schwannoma (2) HBL (1) Meningioma (1) Pitu. adenoma (1) Chondrosarc. (1) |
|
| Sampling site (n) |
||||||
| Cisternal Lumbar Ventricular |
0 11 0 |
10 2 0 |
0 12 10 |
2 9 0 |
1 6 2 |
|
| External Validation Cohort (n = 23) | ||||||
| Group | Total |
Healthy Control
(n = 6) |
LM
(n = 11) |
Brain Metastasis
(n = 6) |
||
| Gender | ||||||
| Male | 10 | 2 | 7 | 1 | ||
| Female | 13 | 4 | 4 | 5 | ||
| Median age (range) |
65 (39–73) |
59 (45–73) |
69 (63–71) |
64 (39–66) |
||
| Primary disease (n) |
Unruptured An. (4) HTN (2) |
NSCLC (11) | NSCLC (1) Breast ca. (5) |
|||
| Sampling site (n) | ||||||
| Cisternal Lumbar Ventricular |
2 3 1 |
0 6 5 |
2 3 1 |
|||
Abbreviations: An, aneurysm; GCT, germ cell tumor; HBL, hemangioblastoma; HCC, hepatocellular carcinoma; HTN, hypertension; LM, Leptomeningeal metastasis; NSCLC, non-small cell lung cancer.